Percutaneous transvenous angioplasty in the treatment of vascular access stenosis  by Beathard, Gerald A.
Kidney International, Vol. 42 (1992), pp. 1390—1397
Percutaneous transvenous angioplasty in the treatment of
vascular access stenosis
GERALD A. BEATHARD
Austin Diagnostic Clinic, Austin, Texas, USA
Percutaneous transvenous angioplasty in the treatment of vascular
access stenosis. This study was undertaken to evaluate percutaneous
transvenous angioplasty (PTVA) for the treatment of all types of
vascular access stenosis in a large population of dialysis patients.
Stenoses were identified by venography in patients who met a set of
clinical criteria indicating the need for evaluation. The lesions were
classified by location and type. Data were collected prospectively and
analyzed separately for each lesion type. A total of 536 PTVA proce-
dures was performed in 285 patients. This included 107 cases of long
venous stenosis (>6 cm) and 149 cases of mid-graft stenosis. In the total
group, an initial success rate of 94% was obtained (80% or greater
dilatation). A decrease in VPm (venous pressure measured on dialysis)
of 35.9%, 32.4%, and 22.6% was seen at one week, one month, and
three months, respectively. At 90 days, 180 days, and 360 days 90.6%,
61.3%, and 38.2%, respectively, of the treated grafts were continuing to
be patent and functional with no need for repeat PTVA treatment.
Repeat treatments for recurrent lesions were as successful as the initial
treatment. It is concluded that vascular access stenosis can be easily
diagnosed and that all categories of stenotic lesion can be effectively
treated with PTVA.
A patent vascular access capable of providing a blood flow of
at least 300 ml/min is essential for successful long-term hemo-
dialysis. The preferred mechanism for providing this access is
the creation of an autogenous radial-cephalic arteriovenous
fistula [11. For one of a variety of reasons, however, this type of
fistula is not possible in most patients. The use of a graft of
expanded polytetrafluroethylene (PTFE) has become an accept-
able alternative in these cases.
The major chronic problem encountered in patients using
PTFE grafts has been the maintenance of patency. Reported
patency rates at one year have varied from 55% to 75% [2—6],
with stenosis being the most common factor leading to a loss of
patency. Stenosis most frequently occurs at the graft-vein
anastomosis, but may occur anywhere within the vein proximal
to the graft or within the graft itself [5, 7, 8]. The venous lesions
are secondary to intimal hyperplasia and perivenous fibrosis [5,
8], Intragraft stenosis (mid-graft stenosis) has been attributed to
pseudointimal hyperplasia [8] and fibroblastic ingrowth through
needle puncture tracts [9].
In general, the treatment of these lesions has been delayed
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until dialysis has become difficult or impossible because of
extremely high venous pressure, recirculation, clotting of the
graft, or excessive difficulty placing a needle into the graft. At
this point, treatment has typically consisted of surgical revision.
Although successful in restoring the access to a functional state
[2—5, 8, 10], surgical revision frequently results in the loss of a
segment of vein. Since the lesions tend to be recurrent [5, 8, 10]
this treatment can eventually lead to a depletion of vascular
access sites.
Since 1980, there have been several reports on the usefulness
of percutaneous transluminal venous angioplasty (PTVA) in the
treatment of selected types of stenotic lesions that develop in
association with dialysis access grafts [7, 11—28]. Although
there has been no general agreement as to the best approach for
screening dialysis patients for stenosis, these reports have
shown that, with the exception of long venous lesions and
lesions occurring within the graft itself, PTVA can be used
successfully in their treatment.
Our systematic approach to early detection and routine
application of PTVA as the primary treatment for all types of
stenotic lesions in all patients with PTFE vascular access in a
large dialysis population forms the basis of this report.
Methods
Diagnosis of stenosis
Over the past five years, a systematic approach has been used
to diagnose stenotic lesions involving vascular access grafts in
a group of 425 dialysis patients. Forty-nine percent of these
patients were male, their average age was 54.4 years, 41% were
diabetics, 43% were African-American, 28% were Latin-Amer-
ican, and 27% were European-American. They had been on
dialysis a mean of 44 months (median 30 months) and were all
dialyzed a minimum of four hours three times each week.
Seventeen percent had primary autogenous radio-cephalic ar-
teriovenous fistulas; the remainder all had PTFE grafts.
Patients were evaluated if they met one or more of the
following clinical criteria (Table 1): frequent graft thrombosis (2
or more times in one month), persistent swelling of the access
arm, difficulty with needle placement for dialysis, a persistently
elevated venous pressure measured on dialysis (VPm), or
evidence of significant recirculation (15% or greater). This
evaluation consisted of a physical examination of the access
arm [29] and a venogram to confirm the presence and document
the character and extent of the stenosis,
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Table 1. Incidence of clinical indicators for stenosis
Indicator
Lesion type
Anastomosis Short venous Multiple venous Long venous Mid-graft Subclavian
VPm> mean + 1 sDa 188 (60%) 65 (46%) 32 (86%) 82 (77%) 73 (49%) 16 (59%)
VPm > 2 mean" 44 (14%) 18 (16%) 7 (19%) 24 (22%) 16 (11%) 9 (33%)
Frequent clottinge 108 (34%) 52 (46%) 12 (32%) 32 (30%) 46 (31%) 6 (22%)
Difficult needle placement 4 (0.1%) 1 (0.8%) 0 (0%) 2 (2%) 87 (58%) 2 (7%)
Persistent swollen arm 14(4%) 16(14%) 4 (11%) 12 (11%) 1(0.6%) 18 (67%)
Recirculation" 42(13%) 29(25%) 7 (19%) 22 (21%) 26(17%) 3 (11%)
Data represent the number of cases in each category.
a Using standard technique (persistent)b At blood flow used for treatment (persistent)
Two or more times in one monthd Greater than 15%
Number
Type Definition Frequency Total Isolateda
Anastomosis Graft-vein anastomosis 58.4% 313 170
Short venous Single stenosis in vein
<6cm
21.3% 114 46
Multiple Multiple stenoses in vein 6.9% 37 25
venous <6 cm each
Long venous Long stenosis in vein >6
cm
20.0% 107 54
Mid-graft Within graft 27.8% 149 60
Subclavian Subclavian and
brachiocephalic
5.0% 27 12
Mixed More than one type 33.2% 178 —
Occurring as isolated lesion not part of mixed pattern
et al [26] was used to determine VPm. This consisted of
evaluating the VPm early (within 5 mm) after the initiation of
dialysis at a blood flow of 200 mllmin. Using this technique,
three measurements were done at six month intervals on all
patients in our dialysis units, using the same needle size. Using
this data, a standard VPm for our patient population was
determined. We have referred to this value as our normal VPm.
This value was found to have a mean of 77.4 27.4 mm Hg
using a 16 gauge needle. It has been used for comparison to
determine the presence of an abnormal VPm. Patients were
considered to have an abnormally elevated VPm if it exceeded
100 mm Hg (mean + 1 standard deviation) for three consecutive
treatments or if it consistently rose to a level above 150 mm Hg
(twice the mean) when the blood flow was adjusted to the
standard blood flow used for that patient's treatment.
Only stenotic lesions which reduced the vessel or graft lumen
by 50% or more were considered significant for this study. The
stenotic lesions were classified as to location as shown in Table
2. The following anatomic categories were used: anastomo-
sis—a lesion occurring at the graft-vein anastomosis; short
venous—a single lesion occurring within the vein proximal to
the graft, less than 6 cm in length; multiple venous—multiple
lesions occurring within the vein proximal to the graft each one
of which was less than 6cm in length; long venous—a lesion in
the vein proximal to the graft greater than 6 cm in length;
mid-graft—a lesion within the graft; subclavian—a lesion occur-
ring in the subclavian or brachiocephalic veins; and mixed—a
case having the co-existence of more than one of the individual
lesions.
Angioplasty technique
After obtaining informed consent, PTVA was scheduled in all
patients having a significant lesion of any category. Generally,
even cases with apparent complete obstruction were attempted
since it was learned that in many of these a small persistent
lumen could be identified by passing a guide wire.
The same basic technique was used for all PTVA treatments.
First, a 16-gauge dialysis needle was inserted into the graft as
near to the arterial anastomosis as was practical, pointing in an
antegrade direction. This was used to inject contrast (Isovue-
370, Squibb Diagnostics) and medications. After a small inci-
sion was made through the skin, an 18-gauge thin wall needle
(Baxter Healthcare Corp.) was inserted into the graft slightly
proximal to the first needle in straight grafts or as far distal as
possible on the venous side of loop grafts. A 150 cm Teflon-
coated Bentson guide wire (Cook) was passed through this
needle up to the level of the subclavian vein. In some cases,
tortuosity of a segment of the vein required the use of a glide
wire (Medi-Tech Inc.), which was either straight or with a slight
J on its tip.
Once the guide wire was in place, the opening was dilated
using a 7-F dilator. A balloon catheter (Blue Max, Medi-Tech,
Inc.) was then passed over the guide wire up to the most
proximal site of stenosis; no sheath was used. Balloons of 8 mm
diameter were used routinely, although in large proximal veins,
a 10 or 12 mm balloon was frequently employed. Smaller
balloons were not utilized. The balloon length most frequently
utilized was 8 cm. When these were not available, lengths
ranging from 2 cm to 10 cm were used. All of these catheters
had an external diameter of 7-F and a minimum burst pressure
of 17 atmospheres. The contrast-filled balloon was routinely
inflated to 10 atmospheres of pressure and held for two minutes.
Lesions resistant to dilatation were sequentially subjected to
multiple dilatations (5 to 6) at 10 atmospheres and then at 15
atmospheres of pressure. In some resistant cases, pressures of
20 atmospheres were used. Even with these high pressures,
lesions completely resistant to dilatation were occasionally
seen. The entire procedure was performed under fluoroscopic
observation. A venogram was performed immediately post-
PTVA to document the results of the treatment.
Table 2. Classification of lesions
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A record of the technical results obtained with each PTVA
was maintained using the following categories: 100%, a case
having a normal lumen diameter post-PTVA when compared to
the adjacent normal vein; <100%, a case having less than the
normal lumen diameter but greater than 80% post-PTVA;
<80%, a case having less than 80% normal lumen diameter
following treatment; technical failure, a case in which the
procedure could not be performed technically. The latter two
categories were considered unsatisfactory results in this study.
In some cases, the results of treatment were not equal
throughout the full extent of the lesion or lesions. In these
cases, the technical results category applied was dictated by the
area having the poorest result. This was true regardless of how
much overall improvement may have resulted from the treat-
ment in other more responsive areas within the lesion.
Because this procedure is very painful, patients were given
enough midazolam hydrochloride (Versed, Hoffman-LaRoche)
to produce a state of unresponsiveness for the five to 15 minute
duration of the dilation portion of the procedure. The patient's
EKG, blood pressure, respiration, and oxygen saturation (pulse
oximeter) were monitored continuously. Prophylactic antibiotic
coverage (cephazolin, Squibb) was routinely administered. Hep-
arm was generally not used unless the lumen of a distal lesion
was so small as to be completely occluded by the catheter while
a more proximal lesion was being dilated. A heparinized saline
flushing solution was used. No anti-coagulant was given post-
PTVA.
Hemostasis was obtained following removal of the needle and
catheter by manual compression (average time required was 2
to 5 mm) using a gelatin sponge (Gelfoam, Upjohn Co.). All
procedures were performed as outpatients.
Follow-up
The patients were monitored post-PTVA to determine their
average VPm at one week, one month and three months. This
was done using the standardized procedure described above.
Measurements were recorded for three consecutive treatments
at each of these three time intervals. The average of these three
VPm readings was compared to the pre-PTVA pressure which
was defined as the average of six standardized readings re-
corded at the time of the six consecutive dialysis treatments
immediately prior to the PTVA treatment. This comparison was
used to determine the percent of decrease in VPm produced by
the treatment at each of these three time intervals. The initial
time interval for post-PTVA pressure data collection was de-
layed for one week because of concern about venous spasm that
appeared to occur in some venous lesions post-treatment.
Additionally, all patients were followed to determine the
duration of efficacy (DE) of the PTVA treatment. DE was
defined as the period of time that elapsed before the patient met
the criteria for a repeat angioplasty (50% or greater stenosis),
required surgical revision, or developed a thrombosed graft.
Graft thrombosis at any time post-PTVA was counted as a loss,
even if the stenosis was shown not to have recurred. Repeat
venograms were not performed unless otherwise indicated.
Statistical analysis
Life table analysis data were calculated using the Kaplan-
Meier method. Comparisons between the VPm measured at
different time intervals for the same group were analyzed using
the Wilcoxon signed-rank test for nonparametric data involving
paired samples. The Wilcoxon rank sum test was used to
compare the differences noted between the VPm for different
groups. Comparisons of duration of efficacy (DE) for different
groups were made using the generalized Wilcoxon test for
comparing data derived from life table analysis involving cen-
sored observations. The chi-square test was used to determine
the statistical significance of differences in technical results
observed in the various categories of lesions studied. In all
instances a probability value of 0.05 or less was used to
determine statistical significance.
Results
Identification and character of stenosis
Early in this study, venograms were done to establish the
presence of stenosis prior to scheduling the patient for PTVA.
The indications for this study were the clinical criteria as listed
(Table 1) along with physical evidence of stenosis [29]. In the
total group, the most common indication leading to evaluation
for PTVA was an increased VPm. This was also true for each of
the individual categories with two exceptions. A swollen arm
was the most common indication in the subclavian group and
difficulty with needle placement was most common in the
mid-graft group. Conclusions relating to recirculation cannot be
made since this was not routinely tested. The preliminary
venogram was felt to be unnecessary after a review of 328
consecutive studies revealed significant (50% or greater) steno-
sis in 301 cases (91.7%). Pre- and post-treatment venograms
were done at the time of angioplasty as part of the standard
procedure.
We found no correlations between the presence of stenosis
and any of the demographic characteristics of our patient
population such as patient age, sex, ethnicity, presence of
diabetes, time on dialysis or duration of treatment. Neither did
we find any correlation between any of these characteristics and
the result of therapy.
The distribution of lesion types for the 536 PTVA procedures
is shown in Table 2. The anastomosis lesion was the most
common, occurring in 58.4% of cases. One-third of the patients
had more than one type of lesion (mixed). One-fifth of the
patients had a long venous lesion. These lesions ranged from 6
to 40 cm in length. The mid-graft lesion was present in one-
fourth of the cases. These mid-graft lesions were at times very
short involving only a single site within the graft. In other cases,
the lesion involved two-thirds to three-fourths of the length of
the graft. The arterial end of straight grafts and the arterial side
of 1oop grafts were typically spared even when the degree of
stenosis within the remainder of the graft was severe. Of the
subclavian type lesions, one-third involved the brachiocephalic
vein. No differences were seen within this group; therefore,
they were considered together. Eighteen of the subclavian
cases had a history of prior subclavian dialysis catheter place-
ment on the same side as the stenosis. Six patients had cardiac
pacemaker wires within the stenotic lesion. One of these had
also previously had a subclavian catheter placement. In four
patients no predisposing cause for stenosis was identified.
Angioplasty procedure
During the course of this study, a total of 536 PTVA proce-
dures were performed on 285 patients. Multiple procedures
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Table 3. Patients with multiple PTVAs
Lesion type
Number of PTVA
1 2 3 4 5 6
All 285 130 66 33 15 7
Anastomosis 98 41 18 8 3 2
Short venous 25 11 6 2 1 1
Multiple venous 11 9 3 1 1 0
Long venous 31 12 7 3 1 0
Mid-graft 26 16 8 6 3 1
Subclavian 6 2 2 1 1 0
Mixed 90 46 23 11 4 1
Data represent the number of cases in each category.
were performed on 130 patients. The maximum number of
procedures performed on a patient in the study was six (Table
3). The mean time interval between repeat angioplasties in
patients having no other intervening procedure was 229 days
(median 188 days). The most common problem requiring a
repeat procedure was recurrence of the original lesion. This was
not always the case, however. In one-third of the patients with
venous lesions (all categories), a new lesion had developed
requiring the repeat procedure. Additionally, at times only a
portion of a more complex lesion was found to have recurred.
Except as listed in the complications, no difficulties were
encountered in performing the PTVA procedure. This was true
even for the long venous and the mid-graft lesions.
The technical results obtained are shown in Table 4. Accept-
able initial results, which we defined as 80% or greater dilata-
tion (100% and <100% categories), were obtained in 504 cases
(94%) with 409 cases (76.3%) having 100% dilation. When the
procedure could be performed but the results were unsatisfac-
tory, it was generally due to the presence of a lesion that would
not respond adequately to the pressure of the balloon. In a few
cases, however, the lesion appeared to be elastic, stretching
when dilated but returning to its original size afterwards.
Technical failures occurred in 3.3% of the total cases. These
were due to either a complete obstruction or the presence of
such severe venous tortuosity that a guide wire could not be
passed across the lesion.
Using the general criteria of greater than 80% dilation as
acceptable results, no significant differences were seen when
any category of lesion was compared to any other or to the total
group. However, the proportion of cases having acceptable but
less than complete dilation (<100% category) was greater for
each of the venous lesions (short, multiple and long) than for
the total group or any other individual lesion. These differences
were statistically significant (P < 0.05).
A larger portion of the subclavian lesions fell into the
technical failure category than was the case for other catego-
ries. This difference was significant (P < 0.05). Repeat proce-
dures were not associated with any significant differences in
technical results (P > 0.05).
In 72 patients with venous lesions (all types), a narrow,
well-circumscribed, circumferential stenosis site having the
appearance of a stenotic valve was encountered when PTVA
was attempted. These lesions (VS lesions) were frequently
multiple (1 to 6) and spaced at intervals of 6 to 20 cm. They
were often located within a longer area of stenosis. The location
of the VS lesion within the long segment was not constant and
Table 4. Technical results
Technical
Category 100% <100% <80% failure
Lesion typea
All 409 (76.3%) 95 (17.7%) 14 (2.6%) 18 (3.3%)
Anastomosis 249 (79.5%) 51(16.3%) 8 (2.5%) 5 (1.6%)
Short venous' 76 (66.6%) 23 (20.2%) 4(3.5%) 11(9.6%)
Multiple venousc 23 (62.2%) 13 (35.1%) 1(3.3%) 0 (0.0%)
Long venousc 70 (65.4%) 26 (24.2%) 7 (6.5%) 4 (3.7%)
Mid-graft 130 (87.2%) 16 (10.7%) 1(0.7%) 2 (1.3%)
Subclavianc 21(77.8%) 3 (11.1%) 0 (0.0%) 3 (11.1%)
Mixed 135 (75.8%) 30 (16.8%) 7 (2.1%) 6 (3.4%)
PTVAb
#1 214 (75.1%) 53 (18.6%) 6 (2.1%) 12 (4.2%)
#2 97 (74.6%) 28 (21.5%) 3 (2.3%) 2 (1.5%)
#3 51(77.3%) 10 (15.2%) 4 (6.0%) 1(1.5%)
#4" 31(93.9%) 2 (6.0%) 0 (0.0%) 0 (0.0%)
#5" 11(73.3%) 2 (13.3%) 1(6.6%) 1(6.6%)
#6" 5 (71.4%) 0 (0.0%) 0 (0.0%) 2 (28.6%)
Data represent the number of cases in each category.
a Data listed are for isolated lesion type not part of mixed pattern
unless indicated as all or mixed
b Data listed are for primary treatment and repeat treatments as
indicated
C Difference when compared to total group was significant (P < 0.05)d Not tested for significance of difference because of size of group
could not be identified except when the angioplasty balloon was
inflated. In 17% of the cases, the VS lesion could not be broken
even with pressures of 20 atmospheres. In 27%, the VS lesion
appeared to resolve by stretching and in 56% by breaking.
Complications occurred in 16 patients (3%). One patient had
an allergic reaction to the contrast agent, four patients (7.4%)
clotted their grafts during or shortly after the procedure, the
graft was ruptured in one case (0.2%), and in 10 cases (1.9%) a
ruptured vein occurred as recognized by either the extravasa-
tion of contrast or the development of a hematoma. The access
was lost in only two patients (0.4%), both of whom experienced
venous rupture. One of these occurred when a resistant VS
lesion finally broke. Not recorded as a complication was the
fact that small ecchymotic areas along the course of the vein
were occasionally seen the day following PTVA. These were
not associated with a hematoma.
Follow-up
Follow-up data were collected separately for several different
categories within the group: the total group, each type of lesion
occurring alone, cases with mixed lesions, repeat PTVA treat-
ments, and patients with different degrees of technical result.
All data were collected prospectively.
Two parameters were followed to observe the results of the
PTVA treatment: changes in venous pressure measured on
dialysis (VPm) using our standardized technique and duration
of efficacy (DE) for the treatment, as previously described.
The VPm pre-treatment and the decrease in VPm expressed
as the mean percentage decrease is shown in Table 5. The
pre-treatment VPm for the total group of patients was elevated
to a mean of 116 35.3 mm Hg, in contrast to the normal VPm
in our units of 77.4 27.4 under these standardized conditions.
This difference was statistically significant (P < 0.001). The
difference between the normal and the pre-treatment VPm for
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Table 5. Venous pressure (VPm)
Category
pre-treatment
mm Hg
% Decrease post-PTVA
1 week1 1 month1 3 months1
Normal 77.4 27.4 — — —
Lesion typea
All 115.6 35.3' 36.5 23.3% 32.2 25.7% 22.0 28.1%
Anastomosis 115.7 36.1 35.9 26.3% 32.4 27.1% 22.6 31.6%
Short venous 107.2 27.2 28.4 22.8% 27.6 20.6% 10.3 22.6%
Multiple venous 133.1 25.V' 33.9 27.5% 28.6 21.6% 12.1 27.0%
Long venous 127.8 282d 35.5 31.1% 31.2 18.4% 20.1 21.1%
Mid-graft 95.3 33.7" 41.3 25.8% 34.4 25.7% 16.5 37.2%
Subclavian 121.7 46.3 24.8 10.0% 22.3 21.1% 12.2 17.0%
Mixed 117.3 34.4 39.7 19.3% 34.8 27.1% 27.4 22.4%
PTVAb
#1 117.8 36.9 37.0 21.5% 37.0 21.5% 25.5 28.2%
#2 114.8 33.8 34.0 27.9% 32.9 25.9% 18.3 29.9%
#3 113.9 30.4 39.4 20.5% 31.8 28.9% 31.8 23.9%
#4 105.7 31.9 38.8 20.9% 31.2 21.6% 38.8 24.7%
#5 102.9 26.5 50.8 18.9% 27.8 25.3% 18.4 9.6%
#6 113.0 39.6 51.4 16.2% 42.6 9.4% 6.8 5.4%
Technical results
100% 111.6 337a 38.7 23.2% 33.7 26.1% 22.7 28.5%
<100% 127.0 36.7e 30.9 22.6% 28.7 23.2% 18.1 27.8%
a Data listed are for isolated lesion type, not part of mixed pattern unless indicated as all or mixed
b Data listed are for primary treatment and repeat treatments as indicated
' Difference when compared to normal was significant (P < 0.001)
d Difference when compared to total group (all) was significant (P < 0.05)
e Difference between two categories at all time intervals was significant (P < 0.05)
Difference at all three time intervals compared to pre-treatment values was significant for all categories (P < 0.001)
each of the individual categories was also statistically signifi-
cant (P < 0.001).
When the pre-treatment VPm for each type of lesion occur-
ring alone was compared with the total group, significantly
higher values were found for multiple venous and long venous
lesions, while mid-graft lesions had a significantly lower value
(P < 0.05). Additionally, the pre-treatment VPm for patients
with a technical result of 100% was significantly lower than that
for <100% (P = 0.001). Analysis of differences for those cases
with a lesser degree of technical result was not done due to the
small size of these latter categories.
The decrease in VPm expressed as the mean percentage
decrease compared to the pre-treatment level measured under
the standardized conditions described is also shown in Table 5.
In the total group the mean decrease ranged from 36.5%
(median 38.5%) at one week to 32.3% (median 36.6%) at one
month, and 22.0% (median 25%) at three months. These de-
creases were statistically significant at all three time inter-
vals (P = 0,001). In 11% of the cases a decrease in VPm of less
than 10% was seen at one week, even though an accept-
able (80% or greater) technical result had been obtained at the
time of the PTVA.
The decreases seen at each of the time intervals were
statistically significant (P = 0.001) for the total group and for
each subcategory. Repeat PTVA treatment results did not differ
significantly from those obtained with the primary treatment.
The percent decrease for cases with a technical result of <100%
was less than that for 100% cases at all three time intervals.
These differences were highly significant statistically (P =
0.001).
The duration of efficacy (DE) for PTVA treatments in these
patients is shown in Table 6. For the total group, life table
analysis revealed a DE of 90.6% at 30 days, 78.9% at 90 days,
61.3% at 180 days, and 37.8% at 360 days.
When the DE for each type of lesion occurring alone was
compared to the total group, no significant differences were
seen (P > 0.05). Likewise, no significant differences were seen
when the results for those cases with a mixed lesion were
compared to those for the total group (P> 0.05).
The DE for long venous, mid-graft and subclavian lesions
occurring alone was not as good as that for anastomosis lesions,
the group with the best individual results. These differences
were statistically significant (P = 0.001 to 0.01). All subclavian
cases associated with cardiac pacemaker wires had uniformly
poor results post-PTVA even though it was possible to dilate all
of them to normal diameter.
No significant difference was seen for the DE obtained for
repeat PTVAs and the primary treatment. Cases with a techni-
cal result of <100% did not differ significantly from those of the
100% category when the DE for the two groups was ana-
lyzed (P > 0.05).
If a lesion which appeared to be a complete occlusion on
venography could be treated, it behaved in the same manner as
any other lesion of that anatomical category. The fact that the
vein had originally appeared to be occluded did not influence
the immediate or long-term success of the treatment. This was
true regardless of the apparent length of the occlusion. The only
factor influencing the treatment in these cases was whether or
not a guide wire could be passed through the venous segment.
Approximately 20% of the total group of patients required a
follow-up procedure within three months of the PTVA treat-
ment. In 5% this procedure was a repeat PTVA, in 7.5% it was
a surgical revision, and in 7.5% a thrombectomy was necessary.
During the period of this study the rate of surgical revision of
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Table 6. Duration of efficacy (DE)
Time penod days
30 60 90 180 360 720
Lesion types
AI1C 90.6 85.6 78.9 61.3 38.2 22.0
Anastomosis 95.5 91.2 84.2 67.2 43.9 31.0
Short venous 84.0 82.9 80.0 53.7 36.2 14.0
Multiple venous 91.6 86.4 80.2 52.1 23.2 9.8
Long venousd 81,1 76.1 69.5 55.0 32.0 10.1
Mid graftd 94.0 91.0 76.0 55.9 17.8 6.2
Subclavian" 70.4 62.1 48.6 28.9 — —
Mixed 90.0 82.4 76.9 59.0 39.6 21.2
PTVAb
#ie 89.2 82.6 75.7 62.3 43.9 25.2
#2 92.9 90.8 86.1 60.6 30.0 14.0
#3 90.3 83.2 73.2 49.1 20.7 —
#4 92.7 89.7 82.6 59.5 24.6 —
#5 85.7 77.9 60.6 — — —
Technical results
100%f 94.4 89.6 81.7 61.7 37.3 22.2
<100% 87.6 80.2 73.2 56.9 38.8 14.4
Data represent the percentage of cases persisting at each time interval determined by life table analysis.
Data listed are for the isolated lesion type, and are not part of mixed pattern unless indicated as all or mixed
b Data listed are for primary treatment and repeat treatments as indicated
C Differences when each category was compared to total group (all) were not significant (P > 0.05)d Differences when each of these groups was compared to anastomosis group were significant (P 0.001—0.01)
Differences in repeat treatment categories were not significant (P > 0.05)
Differences in technical results categories were not significant (P> 0.05)
grafts in our dialysis units was 0.09 per patient year and the rate
for new graft placement in established patients was 0.08 per
patient year.
Discussion
The delivery of adequate long-term dialysis is heavily depen-
dent upon the maintenance of an adequately functioning vascu-
lar access. In most dialysis units, the most common means by
which this is provided is a PTFE graft. Unfortunately, the
natural history of these grafts is characterized by the develop-
ment of stenoses [2—5]. In order to provide adequate dialysis
therapy on a continuing basis and to insure vascular access
longevity, these stenotic lesions should be diagnosed early and
treated effectively [26].
From our experience, we feel that the most effective ap-
proach to the detection of vascular access stenosis is the use of
a group of clinical indicators (Table 1). By using these clinical
indicators along with observing the physical findings of steno-
sis, we have been able to achieve a diagnostic sensitivity greater
than 90% [29].
We agree with Schwab et al [26, 301 that once venous stenosis
is detected it should be corrected. It is only by doing this that
graft function and longevity can be maintained. The alternative
to PTVA is surgical revision. PTVA has the advantages of being
a shorter procedure than surgical revision, causes less stress to
the patient, obviates the need for hospitalization, enables
immediate dialysis without the need for a central venous
catheter, has less chance of infection and saves the patient's
veins. For these reasons, we have adopted PTVA as the initial
treatment for these lesions.
The fact that stenoses recur following PTVA should not
detract from its value when compared to surgery. Etheredge et
al [10] reported 30-day success rates following surgical revision
of dialysis access grafts of 65%, 53%, and 44% for first, second
and third revisions, respectively. In a retrospective compara-
tive study, Dapunt et al [22] found the success rate for PTVA to
be superior to that for surgery. In our units, we have found the
percentage of graft patency at six months following surgical
thrombectomy and surgical revision to be 32% and 37%,
respectively. It is important to realize, however, that these two
groups are not comparable to the PTVA group. In both of the
surgical groups, the grafts were generally thrombosed prior to
treatment. In the PTVA group, the grafts were still patent at the
time of treatment.
Unlike other investigators [7, 18, 19, 23, 261, we did not find
that the long venous lesions present a problem. Lesions varying
in length from 6 to 40 cm were dilated successfully. Although
the duration of success for these patients was not as good as for
the best category (anastomosis) in our series, it did not differ
significantly from any other lesion type or from the total group.
An apparent total occlusion of the vein does not appear to
affect the results obtained with PTVA as long as the treatment
can be performed. This is true regardless of the length of the
lesion. If the treatment can be performed it simply means that
the occlusion was only apparent and not real. Unfortunately,
this cannot be determined until an attempt is made to pass a
guide wire.
When seen, the VS lesion presents a significant problem.
From its appearance, we feel that this may be the valvular
stenosis that has been alluded to by others [31]. We found this
lesion to be very difficult, frequently resisting pressures as high
as 20 atmospheres. Only one-half of these could be broken and,
in one instance, attempts to break the lesion lead to rupture of
the vein and loss of the access.
The reasons for the poor long-term success of the subclavian
lesions in this series is not clear. Perhaps a larger series would
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be more informative. It is possible that a larger balloon or,
perhaps, a combination of two balloons as was used by Schwab
et al [32] might have given better results. There certainly
appears to be an advantage in using a balloon that is slightly
oversized in comparison to the size of the vein. The frequency
with which central venous stenosis was associated with cardiac
pacemaker wires and the poor results obtained in these cases
post-PTVA suggest that this situation should be avoided if
possible.
The mid-graft stenosis represents a unique situation. Unlike
the other lesions that cause stenosis, mid-graft lesions are not
secondary to intimal hyperplasia or perivenous fibrosis [2—5].
The primary indication for evaluation of these cases was
difficulty with needle placement at the time of dialysis. As
shown in Table 5, the pre-treatment VPm for this group was
significantly lower than that for the total group. The initial
success rate for this group was as good as with other types of
lesions. The duration of success was not as good as the best of
the groups (anastomosis), but did not differ significantly from
the total group. This lesion can develop and recur very quickly.
We have seen one case in which a severe lesion occurred in a
new graft that had been in place for only three months.
We had only one immediate complication in treating the 149
cases of mid-graft stenosis in this series and have seen no
long-term complications over the five years of the study. There
was no problem in fully inflating an 8 mm balloon within the
PTFE grafts, although the grafts used in our patients are
generally 7 mm in diameter. The grafts appeared to dilate only
slightly even though the lumen opened readily with the appli-
cation of 10 to 15 atmospheres of pressure. This fact suggests
that the material causing the narrowing and irregularity was
either squeezed out or compressed. We observed no clinical
evidence of embolization or systemic ill effects in these pa-
tients. Treatment of recurrences has been as successful as the
primary treatment.
All investigators who have studied the treatment of stenotic
lesions affecting dialysis access grafts have stressed their recur-
rent nature. This does not appear to be a critical problem since
repeated treatment is possible and has the same degree of
success as the initial procedure. Additionally, if surgery is
required at a later date, it is basically the same procedure that
would have been performed had PTVA not been done.
This study confirms the success of PTVA in the treatment of
stenotic lesions affecting dialysis access grafts in a large series
where it has been applied systematically to treat all patients
with all types of lesions. We have found that the lesions can be
easily diagnosed and that the PTVA procedure can be per-
formed easily and safely. We have encountered a high level of
patient acceptance and a preference over surgery. The only
major problem has been that of recurrence, which is not unique
to PTVA.
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